GW Pharma (GWPH) Posts Q3 Loss of 6c/Share; THCV Phase 2 Missed Primary Endpoint in T2D
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress
August 9, 2016 7:01 AM EDT- Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) - - Positive FDA pre-NDA meeting - NDA for Dravet syndrome and LGS on track for H1 2017 submission - Â Â Â Â Â Â Â Â Â Â Â Â -Conference call today at 8:30 a.m. EDT, 1:30 p.m. BST -
LONDON, Aug. 09, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH) (AIM: GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced... More
